New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 4, 2014
16:01 EDTLJPCLa Jolla announces completion of enrollment of Phase 2 study of GCS-100
La Jolla Pharmaceutical announced that it has completed enrollment of GCS-100-CS-4003, its Phase 2 Extension study of GCS-100 in chronic kidney disease. The 4003 study was initiated to study the long-term safety and efficacy of GCS-100 in patients who completed the initial 12-week Phase 2 study. A total of 93 patients enrolled across 5 sites. Initial data from the 4003 Extension study is expected late this year.
News For LJPC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for LJPC

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use